ESC 365 - Effects of SGLT2 inhibitor dapagliflozin in a non-diabetic hypertensive model of heart failure with preserved ejection fraction

Open Access

Effects of SGLT2 inhibitor dapagliflozin in a non-diabetic hypertensive model of heart failure with preserved ejection fraction

Session: LBS Poster Session 2

Topic: Heart Failure

Speaker: Doctor D. Cappetta (Naples, IT)

Event: Frontiers in CardioVascular Biology 2018

Congress Presentation

Add to my library

About the speaker

Doctor Donato Cappetta

Second University of Naples, Naples (Italy)

2 presentations

0 follower

5 more presentations in this session

Elevated measured cardiac troponin T in skeletal myopathies - re-expression in skeletal muscle or assay cross-reaction?

Speaker: Doctor J. Schmid (Graz, AT)

Extracellular microRNA as new predictive biomarkers of acute kidney injury after coronary bypass graft surgery

Speaker: Doctor G. Biglino (Bristol, GB)

Dipeptidyl peptidase 4 inhibitor sitagliptin ameliorates cardio-renal axis in Dahl salt-sensitive hypertensive rat model

Speaker: Doctor D. Cappetta (Naples, IT)

Combined genetic and electrophysiological studies resolve an unexplained SCD case

Speaker: Ms A. Nijak (Antwerp, BE)

Implantation of tissue-engineered patches for correction of heart defects in a large animal model

Speaker: Miss A. Albertario (Bristol, GB)

Access the full session

LBS Poster Session 2

Speakers: Doctor D. Cappetta, Doctor J. Schmid, Doctor G. Biglino, Doctor D. Cappetta, Ms A. Nijak...

About the event

Frontiers in CardioVascular Biology 2018

20 April - 22 April 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources